RadNet

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RadNet reports strong Q4 earnings, targets AI growth in 2023

RadNet's Q4 2022 performance demonstrated strong revenue and EBITDA growth, fueled by procedural demand and strategic investments in AI and expansion initiatives.
Despite challenges like labor market disruptions and a net loss, the company's focus on innovation, market positioning, and financial discipline bodes well for future profitability and growth.
Opportunities lie in AI revenue growth, de novo center profitability, and market expansion, positioning RadNet as a key player in the radiology industry with a clear path to sustained success.
With a commitment to quality services, shareholder value, and operational excellence, RadNet's strategic vision aligns with industry trends and growth opportunities, setting the stage for continued success and market leadership.

RadNet reports record Q1 revenue and EBITDA growth, eyes AI expansion

RadNet's Q1 2023 showcased strong financial performance and operational improvements. Despite challenges like net loss and labor inflation, the company is strategically positioned for growth through expansion and AI initiatives. Opportunities in advanced imaging services and cancer detection technologies present avenues for future success.

RadNet reports record Q2 earnings, eyes growth amid challenges

RadNet's Q2 2023 performance reflects strong revenue and EBITDA growth, driven by core Imaging Center segment.
While facing challenges like potential Medicare cuts and AI segment delays, the company is optimistic about growth opportunities.
Strategic initiatives in preventative medicine, AI, and outpatient services position RadNet for future success.
With a focus on innovation and financial strength, RadNet aims to capitalize on market shifts and technological advancements.

RadNet reports robust Q3 earnings, eyes growth through AI and partnerships

RadNet's Q3 performance reflects strong revenue growth and financial management, supported by AI division success and strategic initiatives for 2024.
Despite challenges such as staffing shortages and pricing discussions, the company's strengths in liquidity, debt management, and operational focus position it well for future growth.
Opportunities in acquisitions, AI investments, and partnerships offer avenues for expansion and innovation, driving RadNet's market leadership and service excellence.
Overall, RadNet's focus on growth, efficiency, and strategic partnerships underscores its commitment to sustainable success and market resilience in the healthcare industry.

RadNet reports record Q4 earnings, eyes AI growth opportunities

RadNet's Q4 2023 performance was strong, with record revenue and adjusted EBITDA driven by Imaging Center segment growth.
The company's focus on AI, acquisitions, and joint ventures presents growth opportunities but also challenges in reaching expansion targets.
Management's commitment to market leadership and financial strength positions RadNet well for future success and innovation.
RadNet's strategic investments and balance sheet strength support its growth initiatives and potential breakthroughs in AI solutions.

RadNet achieves record Q3 results, eyes AI growth opportunities

RadNet's Q3 2024 performance showcased exceptional financial results, underpinned by revenue growth, operational efficiency, and strategic guidance revisions for the full year.
The company's strengths lie in expansion initiatives, innovative collaborations, and a forward-looking approach towards technology commercialization and digital health advancement.
While facing challenges in regional adoption rates and program implementations, RadNet is well-positioned to capitalize on opportunities through strategic partnerships, AI profitability, and market expansion efforts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RadNet (RDNT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in RadNet (RDNT): Can Its 5.4% Jump Turn into More Strength?

LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its second quarter 2021 financial results on Monday, August 9th, 2021 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its Second Quarter 2021 Financial Results Conference Call

LOS ANGELES, June 28, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Greg Sorensen, President of RadNet's DeepHealth artificial intelligence division, will be hosting a call with Jefferies equity research analysts, Brian Tanquilut and Anthony Petrone, on Wednesday, June 30, 2021 at 1:00 p.m. Eastern Time.

RadNet, Inc. and Jefferies to Host a Teach-In on Artificial Intelligence within Diagnostic Imaging

Alzheimer's disease patients who take Aduhelm will need a lot of diagnostic scans, too. Imaging leader RadNet stands to benefit.

Did This Company Just Win Big Because of Biogen?

RadNet (RDNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

RadNet (RDNT) Soars 10%: Is Further Upside Left in the Stock?

LOS ANGELES, May 26, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Jefferies 2021 Virtual Global Healthcare Conference on Thursday, June 3, 2021 at 2:30 p.m. Eastern Time.

RadNet, Inc. to Present at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021

RadNet, Inc. (RDNT) CEO Howard Berger on Q1 2021 Results - Earnings Call Transcript

RadNet (RDNT) delivered earnings and revenue surprises of 180.00% and 7.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Q1 Earnings and Revenues Beat Estimates

Shares of RadNet (NASDAQ:RDNT) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 112.12% year over year to $0.04, which beat the estimate of ($0.03).

RadNet: Q1 Earnings Insights

LOS ANGELES, May 10, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 346 owned and/or operated outpatient imaging centers, today reported financial results for its first quarter of 2021.

RadNet Reports First Quarter Financial Results, Including Record First Quarter Revenue, Adjusted EBITDA(1) and Net Income, and Revises Upwards 2021 Financial Guidance Ranges

RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RadNet (RDNT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

GREENVILLE, S.C., May 3, 2021 /PRNewswire/ -- eRAD, a subsidiary of RadNet, Inc. (NASDAQ: RDNT), a leading provider of RIS (Radiology Information System) and PACS (Picture Archiving and Communication System) solutions, announced today that Shields Health Care Group has successfully deployed eRAD's RIS across all of its imaging locations.

Shields Health Care Group Deploys eRAD RIS to Streamline Efficiency Across Enterprise

LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2021 financial results on Monday, May 10th, 2021 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces the Date of its First Quarter 2021 Financial Results Conference Call

LOS ANGELES, April 26, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and/or operated outpatient imaging centers, today announced the successful closing of the previously announced refinancing of its senior secured first lien term loan facility and senior secured revolving credit facility pursuant to the terms of a Second Amended and Restated First Lien Credit and Guaranty Agreement (the “Second Amended and Restated Credit Agreement”).

RadNet Announces the Closing of Its Previously Announced Refinancing Transaction

RadNet (RDNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

RadNet (RDNT) Upgraded to Buy: Here's Why

CAMBRIDGE, Mass. and LOS ANGELES, April 19, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc., (NASDAQ: RDNT) today announced that its subsidiary DeepHealth, a leading developer of artificial intelligence (AI) for mammography interpretation, has received FDA clearance for its mammography triage software Saige-Q.

RadNet's Artificial Intelligence Subsidiary, DeepHealth, Announces FDA Clearance for its AI Mammography Triage Software

LOS ANGELES, April 06, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and/or operated outpatient imaging centers, today announced a proposed refinancing transaction for its existing senior secured first lien term loan, which had a balance of $611 million as of December 31, 2020, and its $195 million senior secured revolving credit facility, which was undrawn as of year-end 2020. The Company seeks to replace these facilities with a proposed seven-year $675 million senior secured term loan B facility and a five-year $195 million senior secured first lien revolving credit facility. In addition to repaying the existing $611 million senior secured first lien term loan, the proceeds are expected to pay estimated fees and expenses and fund cash to the Company's balance sheet.

RadNet Announces a Proposed Refinancing Transaction for its $611 Million Senior Secured Term Loan and $195 Million Senior Secured Revolving Credit Facility

LOS ANGELES, March 17, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Spring 2021 Conference on Wednesday, March 24th at 01:00 p.m. Eastern Time.

RadNet, Inc. to Present at the Sidoti & Company Spring 2021 Virtual Investor Conference on Wednesday, March 24th

RadNet, Inc. (RDNT) CEO Howard Berger on Q4 2020 Results - Earnings Call Transcript

RadNet (RDNT) delivered earnings and revenue surprises of 25.00% and 1.82%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Q4 Earnings and Revenues Top Estimates

LOS ANGELES, March 08, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 331 owned and/or operated outpatient imaging centers, today reported financial results for its fourth quarter and full year ended December 31, 2020.

RadNet Reports Fourth Quarter Results with Record Revenue and Adjusted EBITDA and Releases 2021 Financial Guidance

Earnings Preview: RadNet (RDNT) Q4 Earnings Expected to Decline

LOS ANGELES, Feb. 23, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2020 financial results on Monday, March 8th, 2021 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its Fourth Quarter 2020 Financial Results Conference Call

Nation's Largest Radiology Firm Signs Long-Term Lease for 24,000 Square Foot Space In Park Central's Strauss Building; Adds to Medical and Tech Presence in Project Nation's Largest Radiology Firm Signs Long-Term Lease for 24,000 Square Foot Space In Park Central's Strauss Building; Adds to Medical and Tech Presence in Project

RadNet Leases Significant New Space in Phoenix at Park Central

CAMBRIDGE, Mass. and LOS ANGELES, Jan. 11, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) today reported that its DeepHealth subsidiary, a leading developer of artificial intelligence (AI) for mammography interpretation, published results of its novel AI algorithms in Nature Medicine, illustrating an ability to detect breast cancer a year or more earlier than current practice.

News for RadNet Stock (RDNT)